Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.

An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities.

A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow.

Read Executive Editor Rick Berke's letter to STAT readers on "The Deadliest Drug," a new investigative series into the country's failure to address excessive alcohol use.

"People say there's no cure. I say, we just haven't found it yet."

A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.

“No one's pulling the pieces together”: a conversation with medical students about preventive care education.

FDA review confirmed overall safety of 16 brands of baby formula. In a STAT Q&A, experts unpack what low-level PFAS findings mean to worried moms.

Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.

Trump slammed Sen. Bill Cassidy for blocking his surgeon general pick, as he nominated a replacement.

A new tool, OBSCORE, is meant to better define who's at risk for obesity complications, going beyond BMI to include family history, diet, and more.

“I don’t think anyone has the answers. But the conversation needs to start”: medical students on bringing a preventive mindset to medical education.

The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.

Kennedy continues to make waves across health care, but he's pulled back on a number of core MAHA issues.

A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.

How a rare disease drugmaker won FDA approval after a clinical trial disappointed.

The FDA will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain peptides

Beeline Medicine is focused on development of five inflammatory and immune disorder drugs, starting with a potential daily pill for lupus.

CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.

A study is called “really, really important” in showing how teams can induce patients to get their blood pressure under control.

Whoever takes over the CDC next will face immediate and enormous challenges. Here are a few.

A California bill would allow "not ultraprocessed" labels on foods, even as scientists debate definitions and courts question the legality of similar laws.

A new MRI method measures cardiac oxygen use in three minutes without catheters or radiation, offering a simpler way to study heart failure and metabolism.

CMS wants “to turn this shoddy patchwork of care into a seamless tapestry,” write CMS Administrator Mehmet Oz and Center for Medicare and Medicaid Innovation Director Abe Sutton.

JAMA Cardiology study says premature menopause, three times more common in Black women, is a risk factor for heart disease — but scientists aren't sure why.

Perfusion technology vastly improves organ quality in transplants, but high costs and coverage questions pose barriers in becoming the standard of care.

Cardiology groups say adults as young as 30 should assess cholesterol risk and consider treatment to prevent heart attacks and strokes.